PLATO
Platelet Inhibition and Patient Outcomes
Doente / População Intervenção / Exposição Comparação Desfecho
In 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.
N
18 624
Desenho
Double-blind RCT, 12 mo
Desfecho
CV death, MI or stroke at 12 months
Relevância
1
Resultado9.8 % vs 11.7 % (HR 0.84). All-cause mortality also reduced.
Wallentin L, et al. N Engl J Med. 2009;361(11):1045-1057. 10.1056/NEJMoa0904327
Discussão e crítica
Regional heterogeneity (notably worse outcomes in the US sites) prompted FDA scrutiny — attributed to higher aspirin doses. Dyspnoea and bradycardia are notable adverse signals.